Metabolic effects of infection and postnatal steroids

Clinics in Perinatology

Volumn 29, Issue 2, 2002, Pages 295-312

  Schwarzenberg, Sarah Jane ^a   Kovacs, Andras ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUTAMINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; GLUCOCORTICOID; PROTEIN; TRACE ELEMENT;

CATABOLISM; DEVELOPMENTAL DISORDER; DIET THERAPY; DRUG EFFECT; GROWTH DISORDER; GROWTH RETARDATION; HUMAN; INFANT NUTRITION; NEWBORN; NEWBORN CARE; NEWBORN INFECTION; NUTRITIONAL SUPPORT; PERINATAL DEVELOPMENT; PREMATURITY; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; CHILD DEVELOPMENT; ENERGY METABOLISM; INFECTION; LIPID METABOLISM; METABOLISM; NUTRITIONAL REQUIREMENT; SEPSIS;

CHILD DEVELOPMENT; ENERGY METABOLISM; GLUCOCORTICOIDS, SYNTHETIC; HUMAN; INFANT NUTRITION; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFECTION; LIPIDS; MICRONUTRIENTS; NUTRITIONAL REQUIREMENTS; PROTEINS; SEPSIS; GLUCOCORTICOIDS; HUMANS; INFANT NUTRITION PHYSIOLOGY; LIPID METABOLISM;

EID: 0035990691     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(02)00003-9     Document Type: Review

References (93)

1. Nutritional needs of low-birth-weight infants
2. Growth failure and altered body composition are established by one month of age in infants with bronchopulmonary dysplasia
3. Protein requirements of low birth weight, very low birth weight, and small for gestational age infants
4. Growth of low-birth-weight infants
5. Survival and outcome of infants 501 to 750 grams: A six-year experience
6. Catch-up growth, muscle and fat accretion, and body proportionality of infants one year after newborn intensive care
7. Fetal origins of coronary heart disease
8. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women
9. Effect of neonatal caloric deprivation on head growth and 1-year developmental status in preterm infants
10. The hypercatabolic state
11. Stable isotopic quantitation of protein metabolism and energy expenditure in neonates on- and post-extracorporeal life support
12. Can the human neonate mount an endocrine and metabolic response to surgery?
13. The effects of anesthesia and surgery on metabolic homeostasis in infancy and childhood
14. The metabolic needs of critically ill children and neonates
15. Protein metabolism in the extremely low-birth weight infant
16. Dietary composition and macronutrient storage in preterm infants
17. Energy expenditure, energy balance, and composition of weight gain in low birth weight infants fed diets of different protein and energy content
18. Protein needs for term and preterm infants
19. Basic concepts in the determination of nutritional requirements of normal infants
20. Effect of sepsis syndrome on neonatal protein and energy metabolism
21. Urinary 3-methylhistidine/creatinine ratio as a clinical tool: Correlation between 3-methylhistidine excretion and metabolic and clinical states in healthy and stressed premature infants
22. Protein turnover rates in sick, premature neonates during the first few days of life
23. Characteristics of protein and energy metabolism in neonates with necrotizing enterocolitis a pilot study
24. Phenylalanine and tyrosine kinetics in critically ill children with sepsis
25. Maximizing protein nutrition, limits of protein utilization, and interactions between energy intake and protein utilization
26. De novo synthesis of cysteine in premature neonates
27. Phenylalanine hydroxylase activity in preterm infants: Is tyrosine a conditionally essential amino acid?
28. Reduced serum amino acid concentrations in infants with necrotizing enterocolitis
29. Glutamine: A key substrate for the splanchnic bed
30. Enteral glutamine supplementation for very low birth weight infants decreases morbidity
31. Glutamine in the fetus and critically ill low birth weight neonate: Metabolism and mechanism of action
32. Is glutamine a conditionally essential amino acid?
33. Glutamine alimentation in catabolic state
34. Magnitude of the host nutritional response to infection
35. The determinants of protein catabolism in neonates on extracorporeal membrane oxygenation
36. Longitudinal growth of hospitalized very low birth weight infants
37. Energy needs: Assessment and requirements in humans
38. Estimating energy expenditure in critically ill adults and children
39. Energy requirements in sick preterm babies
40. Energy expenditure in 100 ventilated, critically ill children: Improving the accuracy of predictive equations
41. Energy expenditure measurements in ventilated critically ill children: Within- and between-day variability
42. Lipid infusion in premature infants suffering from sepsis
43. Impaired fat utilization in parenterally fed low-birth-weight infants suffering from sepsis
44. Lipid metabolism in the neonate. II. The effect of Intralipid on bilirubin binding in vitro and in vivo
45. Preincubation with intravenous lipid emulsion reduces chemotactic motility of neutrophils in cord blood
46. Intravenous fat emulsions and lung function: A review
47. Postnatal changes in neonatal acylcarnitinc profile
48. Carnitine deprivation adversely affects cardiac performance in the lipopolysaccharide- and hypoxia/reoxygenation-stressed piglet heart
49. Simultaneous measurement of the rates of appearance of palmitic and linoleic acid in critically ill infants
50. Vitamin metabolism and requirements in the micropremie
51. The effect of selenium supplementation on outcome in very low birth weight infants: A randomized controlled trial
52. Randomized controlled study of clinical outcome following trophic feeding
53. Nutritional management and the multisystcm organ failure/systemic inflammatory response syndrome in critically ill preterm neonates
54. Nutrition for ill neonates
55. Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese
56. Parenteral structured triglyceride emulsion improves nitrogen balance and is cleared faster from the blood in moderately catabolic patients
57. Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned
58. Effect ofcorticosteroids for fetal maturation on perinatal outcomes
59. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: A systematic review of RCTs
60. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
61. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants
62. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
63. Growth and growth factors in premature infants receiving dexamethasone for bronchopulmonary dysplasia
64. Controversies in the diagnosis and management of hypotension in the newborn infant
65. Cardiovascular effects of hydrocortisone in preterm infants with pressor-resistant hypotension
66. Effect of corticosteroids on lung function and the clinical course of bronchopulmonary dysplasia in premature infants with a birth weight below 1,500 g
67. Intravenous dexamethasone for extubation of newborn infants
68. Growth in children with chronic lung disease
69. Asthma, steroids, and growth
70. Beclomethasone for asthma in children: Effects on linear growth
71. The effect of dexamethasone on growth, mineral balance and bone mineralisation in preterm infants with chronic lung disease
72. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants
73. Adverse effects of early dexamethasone in extremely-low-birth-weight infants
74. Dexamethasone treatment impairs calcium regulation and reduces bone mineralization in infant pigs
75. Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone
76. Effects of dexamethasone treatment on bone and collagen turnover in preterm infants with chronic lung disease
77. Twenty-month outcome in ventilator-dependent, very low birth weight infants born during the early years of dexamcthasone therapy
78. Control of oligodendrocyte number in the developing rat optic nerve
79. The role of alanine and glutamine in steroid-induced nitrogen wasting in man
80. Dexamethasone increases plasma amino acid concentrations in bronchopulmonary dysplasia
81. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia
82. Catabolic effect of dexamethasone in the preterm baby
83. Glucocorticoid-mediated activation of muscle branched-chain alpha-keto acid dehydrogenase in vivo
84. Glucocorticoid regulation of muscle branched-chain amino acid metabolism
85. Leucine kinetics during simultaneously administered insulin and dexamcthasone in preterm infants with severe lung disease
86. Increased mortality associated with growth hormone treatment in critically ill adults
87. Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study
88. Effects of glucocorticoids on energy metabolism and food intake in humans
89. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease
90. Developmental outcome at 12 months corrected age for infants bom less than 30 weeks gestation: Influence of reduced intrauterine and postnatal growth
91. Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia
92. Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids
93. Glucocorticoids and triglyceride transport: Effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat